

## Invited Mini Review

## The role of extracellular biophysical cues in modulating the Hippo-YAP pathway

Jung-Soon Mo\*

Genomic Instability Research Center (GIRC), Ajou University School of Medicine, Suwon 16499, Korea

The Hippo signaling pathway plays an essential role in adult-tissue homeostasis and organ-size control. In *Drosophila* and vertebrates, it consists of a highly conserved kinase cascade, which involves MST and Lats that negatively regulate the activity of the downstream transcription coactivators, YAP and TAZ. By interacting with TEADs and other transcription factors, they mediate both proliferative and antiapoptotic gene expression and thus regulate tissue repair and regeneration. Dysregulation or mutation of the Hippo pathway is linked to tumorigenesis and cancer development. Recent studies have uncovered multiple upstream inputs, including cell density, mechanical stress, G-protein-coupled receptor (GPCR) signaling, and nutrients, that modulate Hippo pathway activity. This review focuses on the role of the Hippo pathway as effector of these biophysical cues and its potential implications in tissue homeostasis and cancer. [BMB Reports 2017; 50(2): 71-78]

## INTRODUCTION

The size of each organ is determined by cell number and cell size. This process involves many signaling pathways during development, and regeneration controls cell number in tissue and organs. In recent years, the Hippo tumor-suppressor pathway has emerged as a key regulator of organ size and tumorigenesis by inhibiting cell proliferation, promoting apoptosis, and limiting stem/progenitor-cell expansion (1). This pathway was initially identified by means of genetic mosaic screens for growth-control genes. In *Drosophila*, the core components of the Hippo pathway include a kinase cascade of Ste20-like kinase Hippo (Hpo), with the scaffolding protein Salvador (Sav), and NDR family kinase Warts (Wts), with its regulatory protein Mob as Tumor Suppressor (Mats) (2-8). Hpo forms a complex with Sav to phosphorylate and activate Wts,


which then interacts with Mats (9-11). Wts directly phosphorylates the transcriptional co-activator Yki (Yorkie), promoting its interaction with 14-3-3 and leading to YAP cytoplasmic retention (12-16). Inactivation of the Hippo pathway reduces its downstream kinase-mediated YAP phosphorylation. The unphosphorylated YAP translocates to the nucleus, where it binds with the TEAD/TEF- family transcription factor Sd (Scalloped) to activate transcription of target genes, promoting cell survival and proliferation (17, 18). Then the pathway and its cellular functions, including cell survival, proliferation, and organ-size control is evolutionally conserved in mammals (13, 19). Core components of the mammalian Hippo pathway include a kinase cascade of mammalian STE20-like protein kinase 1/2 (MST1/2) and the large tumor suppressor 1/2 (Lats1/2). MST1/2 in complex with its regulatory protein Sav1 phosphorylates and activates Lats1/2 kinases, which also form a complex with its regulatory protein, Mob1. The Yes-associated protein (YAP) is a transcriptional co-activator and an important downstream effector of the Hippo pathway. YAP was first identified as a non-receptor tyrosine kinase YES1 binding partner (20). The physiological importance of YAP/TAZ was uncovered after the identification of *Drosophila* Yki as a key effector of the Hippo pathway (12). In a detailed study of Hippo kinase cascade, the Hippo pathway kinase Lats1/2 inhibits YAP by direct phosphorylation of five consensus HXRXXS motifs (13, 19, 21-23). Phosphorylation of S127 in YAP results in cytoplasmic sequestration via 14-3-3 binding and therefore inactivates YAP. Thus YAP is degraded by the proteasome in a ubiquitin-dependent manner following phosphorylation of Ser 397. A transcriptional co-activator with PDZ-binding motif (TAZ, also called WWTR1), a paralog of YAP in mammals, was initially identified as a 14-3-3 binding protein in a phosphorylation-dependent manner (24). TAZ contains four consensus Lats1/2 target motifs and is similarly regulated by Lats1/2 (23, 25). Conversely, unphosphorylated YAP localizes in the nucleus and acts mainly through the TEAD family transcription factors to stimulate expression of genes that promote proliferation and inhibit apoptosis (26, 27). Besides TEADs, YAP/TAZ can also interact with several different transcription factors, including Smad, Runx1/2, p73, ErbB4, Pax3, and T-box transcription factor 5 (TBX5) to mediate transcription and a diverse array of cellular functions (28).

\*Corresponding author. Tel: +82-31-219-7803; Fax: +82-31-219-7802; E-mail: j5mo@ajou.ac.kr

<https://doi.org/10.5483/BMBRep.2017.50.2.199>

Received 23 November 2016

**Keywords:** YAP, TAZ, Hippo pathway, Mechanical cues, GPCR, Nutrient



**Fig. 1.** Regulation of the Hippo-YAP pathway by extracellular biophysical cues. Mechanical stress inhibits Lats1/2 kinase activity via Rho GTPase and the actin cytoskeleton. GPCR signaling can either activate or inhibit YAP/TAZ activity through the coupled G $\alpha$  protein. Cellular junction and cell polarity modulate the Hippo pathway. Nutrient signaling modulates the core Hippo kinase and YAP activity through AMPK. YAP/TAZ activity is involved in amino-acid induced mTORC1 activation.

In recent years, beyond the main components of the Hippo pathway defined above, many other additional regulators have been found to regulate the Hippo pathway. Accumulating evidence suggests that the core Hippo kinase cascade and YAP/TAZ incorporate various upstream responses, enabling dynamic regulation of tissue homeostasis and cancer (29). In this review we will focus on the expanding roles of YAP/TAZ as mediators of responses to biophysical cues, especially mechanical stress, GPCR signaling, and nutrient signaling (Fig. 1).

## REGULATION OF HIPPO-YAP PATHWAY BY EXTRACELLULAR MECHANICAL CUES

Growth and development is the net result of various harmonized events of cells to adjust to physical restraints and extracellular mechanical signals. For instance, the cell-density-mediated cell-cell contact causes a growth-inhibitory signaling pathway that in large part is mediated by the Hippo pathway (19, 30, 31). Abundant cell-cell contact activates Lats and inactivates YAP which is critically important for contact inhibition. The regulation of YAP/TAZ-TEAD mediated transcription in response to contact inhibition is also essential for embryo development (32). In addition, the apical-basal cell polarity protein, adherens junctions, and tight junctions provide the intrinsic cues to regulate Lats1/2 and restrict YAP activity (33). Interestingly, it was found that YAP/TAZ activity and subcellular localization are regulated by extracellular matrix (ECM) stiffness. When cells are cultured on stiff ECM, YAP/TAZ predominantly localizes to nuclei and promotes

YAP/TAZ transcriptional activity. However, when cells are cultured on soft ECM, cells are round and adhesion with ECM is limited. Likewise, YAP/TAZ activity and subcellular localization depend on the adhesive area. Furthermore, YAP/TAZ activity is modulated by cell stretching, spreading, and cell size through changes in the cytoskeleton (34-36). More importantly, activation of YAP/TAZ by rigidity of the extracellular matrix greatly improves differentiation of human pluripotent stem cells in motor neurons (37).

Morphological manipulation and stress-fiber quantity changes in response to physical forces inhibit the Hippo pathway and promote nuclear YAP localization in a way similar to matrix stiffness (38). Also, induction of F-actin polymerization by loss of capping proteins, Cpa and Cpb, or overexpressing an activated actin nucleation factor Diaphanous, leads to cell proliferation and overgrowth in imaginal discs. Studies on *Drosophila* have demonstrated that changing F-actin levels correlates with activation of Yki and causes overgrowth (39). In contrast, reduction of actin-capping protein or inhibition of Capulet, which all induce abnormal F-actin polymerization, sustains Hippo pathway activity, thereby inducing expression of Yki target genes near the apical surface in *Drosophila* (40). The outcome of F-actin in regulation of YAP is also likely evolutionarily conserved in mammals, since deletion of the destrin gene, an actin-depolymerizing factor, increases the aberrant actin cytoskeleton and leads to epithelial hyperproliferation (41). This was further established by the observation that CapZ or Cofilin restricts YAP nuclear localization and YAP transcriptional activity (35). The structure of actin

cytoskeleton is responsible for the transduction of mechanical stress in cells. The Rho GTPases, which have great effects on actin cytoskeleton organization, is a crucial regulator of YAP/TAZ activity. For example, disruption of F-actin or inhibition of Rho by specific inhibitors considerably reduces YAP nuclear translocation and activity (36, 38, 42). The molecular mechanism of YAP/TAZ regulation by actin cytoskeleton and mechanical stress has not yet been fully understood. Previous studies ignore MST1/2 and Lats1/2 in the regulation of YAP/TAZ nuclear translocation and transcriptional activation, because knockdown of Lats1/2 is not enough to recover YAP/TAZ activity by ECM stiffness (36). However, under detached conditions, the Lats1/2 leads to YAP inhibition in a cytoskeleton-dependent manner (42). Similar to that observed in cell detachment, mechanical strain lead to Lats1/2 inhibition to activate YAP in a JNK-dependent manner (43). Accordingly, it is possible that both Lats1/2-dependent and -independent mechanisms are included in the YAP/TAZ regulation by mechanical stress. Recent findings have implied that YAP/TAZ plays a role in breast-cancer development in response to mechanical stress. For instance, many cancers such as breast cancer have elevated extracellular stiffness accompanied by a changed ECM composition compared with that of normal mammary tissue. Remarkably, it was shown that YAP is activated in cancer-associated fibroblasts (CAFs), and that its function is required for matrix stiffening (44). Higher extracellular stiffness affects YAP activity and hence contributes to the tumor microenvironment. It was proposed that YAP conditioned the tumor microenvironment by modulating matrix stiffening and production of YAP/TAZ target genes, such as AREG, CYR61, and CTGF, to promote tumorigenesis. TAZ is shown to be upregulated in high-grade and metastatic breast tumors (45). In addition, TAZ confers cancer stem-cell traits on breast cancer cells, and cancer stem cells showing high levels of TAZ are observed in high-grade tumors (46). The YAP/TAZ activity and the extracellular matrix provide a positive feedback mechanism, in which cancer cells promote matrix stiffening that further activates YAP/TAZ as transcriptional co-activators. Recent studies also show that disturbed flow activates YAP/TAZ target-gene expression through the modulation of Rho-GTPase activities, demonstrating a significant role for YAP/TAZ in mediating mechanical cues and vascular homeostasis (47-49).

Overall, many studies have suggested that actin Rho-GTPases serves as a sensor to connect mechanical cues to YAP/TAZ activity. However, the involvement of the Hippo pathway kinases MST1/2 and Lats1/2 are not completely understood. Future studies are required to define the mechanotransducers as YAP/TAZ effectors as well as the role of the core Hippo kinase cascade in regulation of YAP/TAZ by mechanical cues.

## REGULATION OF THE HIPPO-YAP PATHWAY BY CELL-SURFACE RECEPTORS AND SOLUBLE MOLECULES

Under normal physiological conditions, hormones are chemical messengers that stimulate cell growth and proliferation. Such molecules are released from the cell sending the signal, cross over the gap between cells by diffusion, and interact with specific receptors in another cell, triggering a response in that cell by activating intracellular signaling which leads to physiological changes inside the cell. Physiological changes that result from soluble molecules tightly regulate cell growth, proliferation, and differentiation. It has been hypothesized that the extracellular environment, such as hormones, might regulate tissue growth and homeostasis through cell-surface receptors and Hippo pathway components. An important discovery came with the demonstration that diffusive lipid molecules, such as lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P), could trigger intracellular signaling cascades and activate YAP/TAZ through their cognate G protein-coupled receptors (GPCRs) (50, 51). Additional study confirmed that both LPA1 and LPA3 are involved in LPA-induced YAP/TAZ activation, which is likely to be relate to long-term cell migration; PP1A is required for the LPA-YAP effects in epithelial ovarian cancer cells (52). Consistent with the roles of LPA and S1P in regulating YAP/TAZ, thrombin, the ligand of protease-activated receptors (PARs), stimulated YAP/TAZ activities by inducing its dephosphorylation and target-genes expression (53). GPCRs recognize numerous extracellular signals and transduce them to heterotrimeric G proteins, which further transduce these intracellular signals to appropriate downstream effectors and thereby play a main role in various signaling pathways (54). Mechanistically, LPA, S1P, and thrombin counteract  $G\alpha_{12/13}$ - and  $G\alpha_{q/11}$ -coupled GPCRs to activate Rho-GTPases. Activation of Rho-GTPase serves as a key mediator in the activation of YAP/TAZ from upstream GPCRs. YAP/TAZ activity could be either activated or inhibited, depending on the G protein coupled to the GPCRs. Activation of  $G\alpha_s$ -coupled GPCRs by epinephrine and glucagon increases Lats1/2 kinase activities and inactivates YAP/TAZ in a manner dependent on protein kinase A (PKA) (55). Hence, depending on the kind of G proteins, GPCRs can differentially regulate Lats1/2 to stimulate or suppress YAP activity. Other studies further demonstrate that the core Hippo kinase cascade and YAP/TAZ activity are regulated by GPCRs in response to various hormonal cues. For instance, GPR68, a proton-sensing GPCR, is activated in response to a decrease in extracellular pH and is required for the pH-dependent regulation of the proliferation and apoptosis. Under a decrease in extracellular pH, GPR68 leads to an increase in the proliferation and a decrease in apoptosis of cells with abundant proton-sensing GPCR expression. In addition, it was found that YAP functions as a potent downstream effector of GPR68 through  $G\alpha_{12/13}$  and Rho GTPase (56, 57). Besides, YAP is required for the pH-

dependent regulation of the differentiation of mesenchymal stem cells (MSCs) into cancer-associated fibroblasts, CAFs. Furthermore, stimulation of the G-protein-coupled estrogen receptor (GPER) by estrogen activates YAP/TAZ and regulates the expression of numerous genes, including well-characterized target genes via the  $G\alpha_{q/11}$ , PLC $\beta$ /PKC, and Rho/Rock signaling pathways. It was proposed that TAZ was required for breast cancer cell proliferation, migration, and tumor growth. As expected, TAZ expression positively correlated with GPER expression in human invasive ductal carcinoma (IDC) specimens, indicating that YAP/TAZ may be activated by estrogen in breast cancer (58). TxA2 exerts its biological activity through its cognate thromboxane A2 receptor (TP) receptor that couples with  $G\alpha_{q/11}$ ,  $G\alpha_{12/13}$ , and other trimeric G proteins to regulate downstream effectors. TP has been implicated in promoting cell migration and proliferation of vascular smooth muscle cells (VSMCs). Treatment of the cells with thromboxane A2 (TP) activation promotes DNA synthesis and induces VSMC proliferation and migration in a manner dependent on YAP/TAZ (59). Thromboxane A2 signaling increases YAP/TAZ activity in VSMCs and other cell types via  $G\alpha_{12/13}$ , providing YAP/TAZ as potential therapeutic target for VSMC-mediated vascular disease. This study shows for the first time that AngII binding to the angiotensin II type 1 receptor (AT1R) can inhibit the Hippo pathway and activate YAP (60). As GPCR's coupling to the G protein subclass  $G\alpha_{q/11}$ , in general, are able to activate YAP, we therefore expected the same influence from the AT1R, which mainly couples to  $G\alpha_{q/11}$ . Stimulation of the AT1R with AngII showed decreased Lats1/2 activation, which was accompanied by decreased phosphorylation of its target YAP in HEK293T cells. Despite the initial observation of AngII as a stimulant of YAP dephosphorylation and nuclear localization, the Hippo pathway is not activated by stimulation with AngII in podocytes, which show a deactivated pathway. However, the actin cytoskeleton disruption with Latrunculin B reactivates Lats1/2 kinase activity, resulting in increased cytoplasmic YAP localization accompanied by a strong induction of apoptosis. Angiotensin II receptor serves as an upstream regulator of the Hippo pathway. The control of Lats1/2 activation and subsequent YAP localization is important for podocyte homeostasis and survival.

In addition to GPCRs, several other morphogenic factors elicit diverse receptor-mediated signaling pathways to control development and tissue homeostasis. The cytokine receptor leukemia inhibitory factor receptor (LIFR) activates the Hippo kinase cascade (61). The PI3K-PDK1 pathway disrupts the core Hippo complex in response to EGF, leading to inactivation of Lats1/2 and activation of YAP (62). Furthermore, YAP/TAZ is a critical mediator of the canonical Wnt/ $\beta$ -catenin and noncanonical alternative Wnt signaling. Two independent groups revealed that Wnt ligands could activate YAP/TAZ through their corresponding GPCRs, frizzled (FZD) receptors, although distinct signaling mechanisms are utilized (63-69). In the present studies, TGF $\beta$  and bone morphogenetic protein (BMP)

sustain YAP/TAZ activity. Interaction between TAZ and TGF $\beta$ -regulated SMAD2 and SMAD3 governs their nuclear localization and target-genes expression. YAP can also be involved with SMAD1 and synergize transcriptional activation of BMP signaling (70-72).

GPCRs are the superfamily of the cell-surface receptors mediating the actions of hundreds of extracellular molecules that have a pivotal role in many physiological functions and in multiple diseases, including the development of cancer and cancer metastasis (54). Elevated expression of GPCRs or activating mutation of  $G\alpha$  leads to aberrant YAP activation and has been found in several types of cancers (58, 73-75). The regulation of YAP/TAZ by GPCRs implies that the Hippo pathway not only is modulated by many extracellular signals and cell-surface receptors, but also contributes to a wide range of physiological regulation and may function as the key mediator of GPCR agonists or antagonists for disease progression.

## REGULATION OF THE HIPPO-YAP PATHWAY BY NUTRIENT SIGNALING

Nutrients and energy metabolism such as glucose, amino acids, and fatty acids are building blocks of the cells that promote cell growth. Glucose is an abundant fuel and the most widely used as an energy source in living organisms. Therefore, it is anticipated that nutrient signals can modulate YAP and TAZ activities. As expected, deprived of glucose, AMPK directly phosphorylates S793 of AMOTL1 and increases AMOTL1 protein levels, resulting in YAP inhibition in a Lats1/2 dependent manner (76). Furthermore, energy stress-activated AMPK directly phosphorylates YAP at multiple sites, and this phosphorylation interferes with the interaction between YAP and TEAD, thus contributing to its inactivation and inhibition of TEAD-mediated transcription (77, 78). LKB/STK11 is a known tumor suppressor and a major upstream regulator of AMPK. LKB1 represses YAP activity via either the core Hippo kinase cascade dependent or independent pathway (79, 80). On the other hand, loss of LKB1 and AMPK contributes to Yki activation and accelerated proliferation in the *Drosophila* (81). LKB1-mediated inhibition of Yki activity is mediated by AMPK and is independent of the Hpo/Wts kinase cascade, suggesting a potential energy-dependent pathway controlling proliferation in the central brain (CB) and ventral nerve-cord developmental neural systems (VNC).

Additionally, the Hippo pathway also responds to nutrients other than glucose. YAP/TAZ potentiates mTORC activity by increasing expression of the high-affinity L-type amino-acid transporter (LAT1), which is a heterodimer of SLC7A5 and SLC3A2. YAP/TAZ and TEAD directly induce transcription of SLC7A5, which rescues SLC3A2 protein expression by dimer formation, to increase LAT1 expression and amino-acid uptake (82, 83). In parallel, mTOR also is a master regulator of cellular growth and survival and stimulates cellular metabolic processes, such as protein synthesis. An mTORC signaling

pathway is reported to drive YAP activation and its target-genes expression in perivascular epithelioid cell tumors and glioblastomas (84-86). Both outputs of TOR are required for wing cells to divide and gain mass under Yki-Sd control in *Drosophila* (87). Previous evidence indicated that YAP, a main target of inhibition by the Hippo pathway, can activate AKT through miR-20-mediated inhibition of PTEN (88). These data, combined with a recent study, indicated that mTORC2 can regulate AKT activity, both directly and indirectly through inhibition of the Hippo pathway and activation of YAP (85). In addition, AKT and MST1 were previously shown to mutually inhibit each other (89, 90). Thus, mTOR2 and the Hippo pathway can engage in crosstalk at multiple levels. Of note, mTORC2 was also shown to activate SGK1 and PRKCA/PKC $\alpha$  (91-93). Besides lowering the cellular cholesterol levels, inhibition of the mevalonate pathway inhibits YAP/TAZ nuclear localization and transcriptional response, possibly because of inhibition of the Rho GTPases, which require a complex network by which cytoskeleton impinges on YAP/TAZ activation (94). In addition, other nutrients have been shown to be important in regulation of the Hippo pathway. For instance, the salt-induced kinases have been implicated in nutrient sensing that promotes Yki target-gene expression and tissue over-growth through phosphorylation of Sav at Ser413 (95).

The most recognized functional output of YAP and TAZ is to promote cell survival and proliferation by cellular nutrient status. Therefore, given the central role of the Hippo signaling pathway in nutrient sensing, understanding how nutrients contribute to cancer development remains an area of intense investigation.

## CONCLUSIONS

Extensive research within recent decades has identified more components and other signaling pathways linked with the Hippo pathway and YAP/TAZ regulation, since many core Hippo-pathway components have been discovered in *Drosophila* and mammals. In recent years, the Hippo pathway has been influentially and intensely regulated by a wide array of extracellular biophysical cues, including mechanical cues, cell-surface receptors, and nutrient signaling from neighboring cells and the extracellular matrix. The core Hippo kinase cascade integrates multiple upstream inputs to control YAP/TAZ activity, allowing vigorous regulation of cellular processes, such as proliferation, differentiation, and apoptosis in intricate physiological contexts and in cancer.

However, it is important to realize that gaps still remain in understanding the key molecular mechanisms in extracellular biophysical cues. For example, it is unclear whether Lats1/2 kinase is involved in YAP/TAZ regulation by actin cytoskeleton under mechanical cues. Current evidence showed that Lats1/2 kinase activity is important for GPCR-mediated YAP/TAZ regulation, but Mst1/2 is not required for YAP/TAZ regulation by both mechanical cues and GPCR signaling. This suggests that

other mechanisms or other unknown molecules may be involved in the process in response to the physiological environment. Furthermore, the detailed mechanism by which the actin cytoskeleton transmits upstream cues to modulate Lats1/2 kinase activity has yet to be uncovered. The possibly existing Lats1/2-independent mechanism of YAP/TAZ regulation by the actin cytoskeleton also has yet to be uncovered. It will also be interesting to define how YAP/TAZ may converge on these mechanical and hormonal cues to respond to the environment in an appropriate manner. For example, both mechanical cues and cell-surface receptors, especially GPCRs, signal input into regulation of Rho GTPase activity and thus affect YAP/TAZ activity.

Taken together, the YAP/TAZ are unquestionably important mediators of extracellular biophysical cues in regulation of organ size control, regeneration, and tumorigenesis, and thus would be legitimate attractive potential therapeutic targets for cancer therapy.

## ACKNOWLEDGEMENTS

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, Ict and Future Planning [NRF-2016R1C1B2016135 (Young Researcher Program), No.2011-0030043 (SRC)] and the New Faculty Research Fund of Ajou University School of Medicine.

## CONFLICTS OF INTEREST

The authors have no conflicting financial interests.

## REFERENCES

1. Yu FX, Zhao B and Guan KL (2015) Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. *Cell* 163, 811-828
2. Harvey KF, Pflieger CM and Hariharan IK (2003) The *Drosophila* Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. *Cell* 114, 457-467
3. Jia J, Zhang W, Wang B, Trinko R and Jiang J (2003) The *Drosophila* Ste20 family kinase dMST functions as a tumor suppressor by restricting cell proliferation and promoting apoptosis. *Genes Dev* 17, 2514-2519
4. Justice RW, Zilian O, Woods DF, Noll M and Bryant PJ (1995) The *Drosophila* tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. *Genes Dev* 9, 534-546
5. Pantalacci S, Tapon N and Leopold P (2003) The Salvador partner Hippo promotes apoptosis and cell-cycle exit in *Drosophila*. *Nat Cell Biol* 5, 921-927
6. Xu T, Wang W, Zhang S, Stewart RA and Yu W (1995) Identifying tumor suppressors in genetic mosaics: the *Drosophila* lats gene encodes a putative protein kinase. *Development* 121, 1053-1063

7. Udan RS, Kango-Singh M, Nolo R, Tao C and Halder G (2003) Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway. *Nat Cell Biol* 5, 914-920
8. Wu S, Huang J, Dong J and Pan D (2003) Hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. *Cell* 114, 445-456
9. Kango-Singh M, Nolo R, Tao C et al (2002) Shar-pei mediates cell proliferation arrest during imaginal disc growth in *Drosophila*. *Development* 129, 5719-5730
10. Tapon N, Harvey KF, Bell DW et al (2002) Salvador promotes both cell cycle exit and apoptosis in *Drosophila* and is mutated in human cancer cell lines. *Cell* 110, 467-478
11. Lai ZC, Wei X, Shimizu T et al (2005) Control of cell proliferation and apoptosis by mob as tumor suppressor, mats. *Cell* 120, 675-685
12. Huang J, Wu S, Barrera J, Matthews K and Pan D (2005) The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the *Drosophila* homolog of YAP. *Cell* 122, 421-434
13. Dong J, Feldmann G, Huang J et al (2007) Elucidation of a universal size-control mechanism in *Drosophila* and mammals. *Cell* 130, 1120-1133
14. Staley BK and Irvine KD (2012) Hippo signaling in *Drosophila*: recent advances and insights. *Dev Dyn* 241, 3-15
15. Oh H and Irvine KD (2008) In vivo regulation of Yorkie phosphorylation and localization. *Development* 135, 1081-1088
16. Ren F, Zhang L and Jiang J (2010) Hippo signaling regulates Yorkie nuclear localization and activity through 14-3-3 dependent and independent mechanisms. *Dev Biol* 337, 303-312
17. Mahoney WM Jr, Hong JH, Yaffe MB and Farnance IK (2005) The transcriptional co-activator TAZ interacts differentially with transcriptional enhancer factor-1 (TEF-1) family members. *Biochem J* 388, 217-225
18. Vassilev A, Kaneko KJ, Shu H, Zhao Y and DePamphilis ML (2001) TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. *Genes Dev* 15, 1229-1241
19. Zhao B, Wei X, Li W et al (2007) Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. *Genes Dev* 21, 2747-2761
20. Sudol M (1994) Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. *Oncogene* 9, 2145-2152
21. Hao Y, Chun A, Cheung K, Rashidi B and Yang X (2008) Tumor suppressor LATS1 is a negative regulator of oncoprotein YAP. *J Biol Chem* 283, 5496-5509
22. Oka T, Mazack V and Sudol M (2008) Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP). *J Biol Chem* 283, 27534-27546
23. Lei QY, Zhang H, Zhao B et al (2008) TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the Hippo pathway. *Mol Cell Biol* 28, 2426-2436
24. Kanai F, Marignani PA, Sarbassova D et al (2000) TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. *EMBO J* 19, 6778-6791
25. Liu CY, Zha ZY, Zhou X et al (2010) The Hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF $\beta$ -TrCP E3 ligase. *J Biol Chem* 285, 37159-37169
26. Zhao B, Ye X, Yu J et al (2008) TEAD mediates YAP-dependent gene induction and growth control. *Genes Dev* 22, 1962-1971
27. Zhang H, Liu CY, Zha ZY et al (2009) TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. *J Biol Chem* 284, 13355-13362
28. Zhu C, Li L and Zhao B (2015) The regulation and function of YAP transcription co-activator. *Acta Biochim Biophys Sin (Shanghai)* 47, 16-28
29. Zanconato F, Cordenonsi M and Piccolo S (2016) YAP/TAZ at the roots of cancer. *Cancer Cell* 29, 783-803
30. Ota M and Sasaki H (2008) Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling. *Development* 135, 4059-4069
31. Nishioka N, Inoue K, Adachi K et al (2009) The Hippo signaling pathway components Lats and Yap pattern Tead4 activity to distinguish mouse trophectoderm from inner cell mass. *Dev Cell* 16, 398-410
32. Gumbiner BM and Kim NG (2014) The Hippo-YAP signaling pathway and contact inhibition of growth. *J Cell Sci* 127, 709-717
33. Yang CC, Graves HK, Moya IM et al (2015) Differential regulation of the Hippo pathway by adherens junctions and apical-basal cell polarity modules. *Proc Natl Acad Sci U S A* 112, 1785-1790
34. Driscoll TP, Cosgrove BD, Heo SJ, Shurden ZE and Mauck RL (2015) Cytoskeletal to Nuclear Strain Transfer Regulates YAP Signaling in Mesenchymal Stem Cells. *Biophys J* 108, 2783-2793
35. Aragona M, Panciera T, Manfrin A et al (2013) A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. *Cell* 154, 1047-1059
36. Dupont S, Morsut L, Aragona M et al (2011) Role of YAP/TAZ in mechanotransduction. *Nature* 474, 179-183
37. Sun Y, Yong KM, Villa-Diaz LG et al (2014) Hippo/YAP-mediated rigidity-dependent motor neuron differentiation of human pluripotent stem cells. *Nat Mater* 13, 599-604
38. Wada K, Itoga K, Okano T, Yonemura S and Sasaki H (2011) Hippo pathway regulation by cell morphology and stress fibers. *Development* 138, 3907-3914
39. Sansores-Garcia L, Bossuyt W, Wada K et al (2011) Modulating F-actin organization induces organ growth by affecting the Hippo pathway. *EMBO J* 30, 2325-2335
40. Fernandez BG, Gaspar P, Bras-Pereira C, Jezowska B, Rebelo SR and Janody F (2011) Actin-Capping Protein and the Hippo pathway regulate F-actin and tissue growth in *Drosophila*. *Development* 138, 2337-2346
41. Ikeda S, Cunningham LA, Boggess D et al (2003) Aberrant actin cytoskeleton leads to accelerated proliferation of

- corneal epithelial cells in mice deficient for destrin (actin depolymerizing factor). *Hum Mol Genet* 12, 1029-1037
42. Zhao B, Li L, Wang L, Wang CY, Yu J and Guan KL (2012) Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. *Genes Dev* 26, 54-68
  43. Codelia VA, Sun G and Irvine KD (2014) Regulation of YAP by mechanical strain through Jnk and Hippo signaling. *Curr Biol* 24, 2012-2017
  44. Calvo F, Ege N, Grande-Garcia A et al (2013) Mechano-transduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. *Nat Cell Biol* 15, 637-646
  45. Chan SW, Lim CJ, Guo K et al (2008) A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. *Cancer Res* 68, 2592-2598
  46. Cordenonsi M, Zanconato F, Azzolin L et al (2011) The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. *Cell* 147, 759-772
  47. Kim KM, Choi YJ, Hwang JH et al (2014) Shear stress induced by an interstitial level of slow flow increases the osteogenic differentiation of mesenchymal stem cells through TAZ activation. *PLoS One* 9, e92427
  48. Wang KC, Yeh YT, Nguyen P et al (2016) Flow-dependent YAP/TAZ activities regulate endothelial phenotypes and atherosclerosis. *Proc Natl Acad Sci U S A* 113, 11525-11530
  49. Sabine A, Bovay E, Demir CS et al (2015) FOXC2 and fluid shear stress stabilize postnatal lymphatic vasculature. *J Clin Invest* 125, 3861-3877
  50. Miller E, Yang J, DeRan M et al (2012) Identification of serum-derived sphingosine-1-phosphate as a small molecule regulator of YAP. *Chem Biol* 19, 955-962
  51. Yu FX, Zhao B, Panupinthu N et al (2012) Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. *Cell* 150, 780-791
  52. Cai H and Xu Y (2013) The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells. *Cell Commun Signal* 11, 31
  53. Mo JS, Yu FX, Gong R, Brown JH and Guan KL (2012) Regulation of the Hippo-YAP pathway by protease-activated receptors (PARs). *Genes Dev* 26, 2138-2143
  54. Lappano R and Maggiolini M (2011) G protein-coupled receptors: novel targets for drug discovery in cancer. *Nat Rev Drug Discov* 10, 47-60
  55. Yu FX, Zhang Y, Park HW et al (2013) Protein kinase A activates the Hippo pathway to modulate cell proliferation and differentiation. *Genes Dev* 27, 1223-1232
  56. Zhu H, Cheng X, Niu X et al (2015) Proton-sensing GPCR-YAP Signalling Promotes Cell Proliferation and Survival. *Int J Biol Sci* 11, 1181-1189
  57. Zhu H, Guo S, Zhang Y et al (2016) Proton-sensing GPCR-YAP Signalling Promotes Cancer-associated Fibroblast Activation of Mesenchymal Stem Cells. *Int J Biol Sci* 12, 389-396
  58. Zhou X, Wang S, Wang Z et al (2015) Estrogen regulates Hippo signaling via GPER in breast cancer. *J Clin Invest* 125, 2123-2135
  59. Feng X, Liu P, Zhou X et al (2016) Thromboxane A2 Activates YAP/TAZ Protein to Induce Vascular Smooth Muscle Cell Proliferation and Migration. *J Biol Chem* 291, 18947-18958
  60. Wennmann DO, Vollenbroeker B, Eckart AK et al (2014) The Hippo pathway is controlled by Angiotensin II signaling and its reactivation induces apoptosis in podocytes. *Cell Death Dis* 5, e1519
  61. Chen D, Sun Y, Wei Y et al (2012) LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. *Nat Med* 18, 1511-1517
  62. Fan R, Kim NG and Gumbiner BM (2013) Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1. *Proc Natl Acad Sci U S A* 110, 2569-2574
  63. Azzolin L, Panciera T, Soligo S et al (2014) YAP/TAZ incorporation in the beta-catenin destruction complex orchestrates the Wnt response. *Cell* 158, 157-170
  64. Barry ER, Morikawa T, Butler BL et al (2013) Restriction of intestinal stem cell expansion and the regenerative response by YAP. *Nature* 493, 106-110
  65. Heallen T, Zhang M, Wang J et al (2011) Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. *Science* 332, 458-461
  66. Rosenbluh J, Nijhawan D, Cox AG et al (2012) beta-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. *Cell* 151, 1457-1473
  67. Varelas X, Miller BW, Sopko R et al (2010) The Hippo pathway regulates Wnt/beta-catenin signaling. *Dev Cell* 18, 579-591
  68. Park HW, Kim YC, Yu B et al (2015) Alternative Wnt Signaling Activates YAP/TAZ. *Cell* 162, 780-794
  69. Azzolin L, Zanconato F, Bresolin S et al (2012) Role of TAZ as mediator of Wnt signaling. *Cell* 151, 1443-1456
  70. Alarcon C, Zaromytidou AI, Xi Q et al (2009) Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways. *Cell* 139, 757-769
  71. Fujii M, Toyoda T, Nakanishi H et al (2012) TGF-beta synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. *J Exp Med* 209, 479-494
  72. Varelas X, Sakuma R, Samavarchi-Tehrani P et al (2008) TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. *Nat Cell Biol* 10, 837-848
  73. Feng X, Degese MS, Iglesias-Bartolome R et al (2014) Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. *Cancer Cell* 25, 831-845
  74. Liu G, Yu FX, Kim YC et al (2015) Kaposi sarcoma-associated herpesvirus promotes tumorigenesis by modulating the Hippo pathway. *Oncogene* 34, 3536-3546
  75. Yu FX, Luo J, Mo JS et al (2014) Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. *Cancer Cell* 25, 822-830
  76. DeRan M, Yang J, Shen CH et al (2014) Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiotensin-like 1 protein. *Cell Rep* 9, 495-503
  77. Mo JS, Meng Z, Kim YC et al (2015) Cellular energy stress

- induces AMPK-mediated regulation of YAP and the Hippo pathway. *Nat Cell Biol* 17, 500-510
78. Wang W, Xiao ZD, Li X et al (2015) AMPK modulates Hippo pathway activity to regulate energy homeostasis. *Nat Cell Biol* 17, 490-499
  79. Mohseni M, Sun J, Lau A et al (2014) A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway. *Nat Cell Biol* 16, 108-117
  80. Nguyen HB, Babcock JT, Wells CD and Quilliam LA (2013) LKB1 tumor suppressor regulates AMP kinase/mTOR-independent cell growth and proliferation via the phosphorylation of Yap. *Oncogene* 32, 4100-4109
  81. Gailite I, Aerne BL and Tapon N (2015) Differential control of Yorkie activity by LKB1/AMPK and the Hippo/Warts cascade in the central nervous system. *Proc Natl Acad Sci U S A* 112, E5169-5178
  82. Park YY, Sohn BH, Johnson RL et al (2016) Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. *Hepatology* 63, 159-172
  83. Hansen CG, Ng YL, Lam WL, Plouffe SW and Guan KL (2015) The Hippo pathway effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1. *Cell Res* 25, 1299-1313
  84. Artinian N, Cloninger C, Holmes B, Benavides-Serrato A, Bashir T and Gera J (2015) Phosphorylation of the Hippo Pathway Component AMOTL2 by the mTORC2 Kinase Promotes YAP Signaling, Resulting in Enhanced Glioblastoma Growth and Invasiveness. *J Biol Chem* 290, 19387-19401
  85. Sciarretta S, Zhai P, Maejima Y et al (2015) mTORC2 regulates cardiac response to stress by inhibiting MST1. *Cell Rep* 11, 125-136
  86. Liang N, Zhang C, Dill P et al (2014) Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. *J Exp Med* 211, 2249-2263
  87. Parker J and Struhl G (2015) Scaling the Drosophila Wing: TOR-Dependent Target Gene Access by the Hippo Pathway Transducer Yorkie. *PLoS Biol* 13, e1002274
  88. Tumaneng K, Schlegelmilch K, Russell RC et al (2012) YAP mediates crosstalk between the Hippo and PI(3)K-TOR pathways by suppressing PTEN via miR-29. *Nat Cell Biol* 14, 1322-1329
  89. Cinar B, Collak FK, Lopez D et al (2011) MST1 is a multifunctional caspase-independent inhibitor of androgenic signaling. *Cancer Res* 71, 4303-4313
  90. Collak FK, Yagiz K, Luthringer DJ, Erkaya B and Cinar B (2012) Threonine-120 phosphorylation regulated by phosphoinositide-3-kinase/Akt and mammalian target of rapamycin pathway signaling limits the antitumor activity of mammalian sterile 20-like kinase 1. *J Biol Chem* 287, 23698-23709
  91. Garcia-Martinez JM and Alessi DR (2008) mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). *Biochem J* 416, 375-385
  92. Ikenoue T, Inoki K, Yang Q, Zhou X and Guan KL (2008) Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. *EMBO J* 27, 1919-1931
  93. Facchinetti V, Ouyang W, Wei H et al (2008) The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. *EMBO J* 27, 1932-1943
  94. Sorrentino G, Ruggeri N, Specchia V et al (2014) Metabolic control of YAP and TAZ by the mevalonate pathway. *Nat Cell Biol* 16, 357-366
  95. Wehr MC, Holder MV, Gailite I et al (2013) Salt-inducible kinases regulate growth through the Hippo signalling pathway in Drosophila. *Nat Cell Biol* 15, 61-71